Zylö Therapeutics

Hoth Therapeutics Announces Positive, Statistically Significant Proof-of-Concept Preclinical Data on its Therapeutic for Cutaneous Lupus Erythematosus (CLE), a Chronic Autoimmune Skin Disease

Ziad2022-11-25T14:02:05-05:00 Hoth Therapeutics, Inc., a biopharmaceutical company, today announced positive, statistically significant proof-of-concept preclinical data on its therapeutic HT-005 for the treatment of Cutaneous Lupus Erythematosus (CLE), a chronic autoimmune skin disease. The study conducted by Jackson Laboratory in partnership with Zylö Therapeutics using a CLE mouse model demonstrated a significant reduction in skin plaque severity after treatment with HT-005-loaded topical Z-pods™ compared to untreated control mice. Read more >>

Jay Blankenship M.D. Joins Zylö as Vice President of Business Development

Ziad2022-11-25T14:02:28-05:00 Zylö Therapeutics Inc., developer of the transformational Z-pod™ topical delivery platform, announced Jay Blankenship M.D. has joined its executive team as vice president of business development. Read more >>

Grapefruit USA, Inc. Commences Production of Its Patented Disruptive Time Release Hourglass(TM) THC+CBD Delivery Cream

Ziad2022-11-25T14:02:28-05:00 Grapefruit USA, Inc., a fully licensed California based cannabis company, is announcing today that it has commenced production of the Hourglass™ time release THC+CBD delivery cream at its manufacturing facility in the Coachillin Canna-Business Park in Desert Hot Springs, California, pursuant to its Exclusive License and Supply Agreement with Zylö Therapeutics Inc. Read more >>

Zylö and Grapefruit Forge Partnership That Promises to Disrupt the Topical Cannabis Market

Ziad2022-11-25T14:02:28-05:00 Zylö Therapeutics Inc., developer of the transformational Z-pod™ topical delivery platform, announced that it has entered into an exclusive agreement with Grapefruit USA, Inc. to supply its Z-pod™ system as the technological underpinning of Grapefruit’s Hourglass™ time-release cannabinoid topical cream. Read more >>

Hoth Therapeutics Provides Shareholder Update on Therapeutics Pipeline

Ziad2022-11-25T14:02:29-05:00 Developed in partnership with Zylö Therapeutics, Hoth's AEA-loaded Z-pods™ are currently being tested for approval in the treatment of Cutaneous Lupus Erythematosus (CLE). Read more >>

Hoth Therapeutics Expands Partnership with Zylö Therapeutics, Inc.

Ziad2022-11-25T14:02:38-05:00 Hoth Therapeutics, Inc., a biopharmaceutical company, today announced it has completed a strategic investment in Zylö Therapeutics, Inc. Mr. Robb Knie, Chief Executive Officer of Hoth, commented, "We are pleased to expand our partnership with Zylö and look forward to working together as our therapeutic for Lupus patients continues through the next phase of development. Read more >>

Hoth Therapeutics Announces Top Line Preclinical Data from Cutaneous Lupus Erythematosus (CLE) Study

Ziad2022-11-25T14:02:38-05:00 Hoth Therapeutics, Inc., a biopharmaceutical company, today announced top line data from its Cutaneous Lupus Erythematosus (CLE) study, a chronic autoimmune skin disease, in partnership with Zylö Therapeutics, Inc. for topical administration of Anandamide (AEA)-loaded Z-pods™. Read more >>

Hoth Therapeutics Announces Positive Preliminary, Preclinical Data on its Therapeutic for Cutaneous Lupus Erythematosus (CLE), a Chronic Autoimmune Skin Disease

Ziad2022-11-25T14:02:39-05:00 The study conducted in partnership with Zylö Therapeutics confirmed AEA-loaded in Z-pods™ provides an actual reduction in lesion score. Read more >>

Venture firm that invests in SC reports record year, pumping $12.7 million into Southeast startups

Ziad2022-11-25T14:02:39-05:00 One of the few venture funds making investments in South Carolina reported another record year in 2019, scaling up its capital outlays by 82 percent from 2018. VentureSouth, which is based in Greenville and has local chapters, focuses on promising companies in the Southeast, including Zylo Therapeutics. Read more >> "

Hoth Therapeutics Initiates Confirmatory Study for Lupus Treatment

Ziad2022-11-25T14:03:25-05:00 Hoth Therapeutics, Inc....today announced initiating a confirmatory study, related to their proprietary AEA-loaded Z-pods in the treatment of Cutaneous Lupus Erythematosus [CLE], a chronic autoimmune disease that affects the skin. The study is being conducted in partnership with Zylo Therapeutics to confirm that topical administration of Hoth's AEA-loaded Z-pods inhibits the development of CLE lesions in a well-established animal model of lupus. Read more >>